Circulating Tumor Cells Market (2025 - 2030)

Circulating Tumor Cells Market Summary

The global circulating tumor cells market size was estimated at USD 12.61 billion in 2024 and is projected to reach USD 24.96 billion by 2030, growing at a CAGR of 12.2% from 2025 to 2030. Owing to their noninvasiveness and advantages, circulating tumor cells (CTCs) are considered a promising tool in cancer diagnosis.

In addition, technological advancements in chip technology are another key factor driving market growth.

Increasing cancer incidence across the globe is one of the major drivers for market growth. In 2023, the Pan American Health Organization reported around 20 million newly diagnosed cancer cases and 10 million cancer-related deaths. Projections indicate a probable 60% surge in the cancer burden over the next two decades, posing additional challenges to healthcare systems, individuals, and communities. It is anticipated that the global incidence of new cancer cases is expected to rise to approximately 30 million by the year 2040. In addition, circulating tumor cells in breast cancer diagnosis are released in the bloodstream by cancerous tumors.

As per Breast Cancer Statistics and Resources, it is anticipated that in 2023, around 297,790 women receive a diagnosis of breast cancer in the U.S., solidifying its status as the most prevalent cancer among American women. The rising burden of cancer also attracts increased investment in research and development for new cancer therapies & technologies. CTCs that actively participate in clinical trials and adopt innovative treatment options can attract patients seeking cutting-edge care, further boosting their market position.

Over the last several decades, extensive translational and clinical cancer research programs have been conducted in the field of CTCs. The ongoing research on circulating tumor cell technology by several government bodies, such as the American Association of Cancer Research and the American Society of Clinical Oncology, to utilize it as a surrogate marker for determining cancer progression is expected to aid market growth.

Furthermore, the rising adoption of biomarker tests enables minimally invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors. Therefore, due to their simpler nature, the high demand for noninvasive procedures is anticipated to considerably impact the CTC market over the forecast period.

Advancements In Chip Technology

The ongoing advancements in chip technology have positively impacted market growth. Cluster chip technology plays a role in capturing the exceptionally rare group of cells, such as CTCs. Isolation of CTCs is a cumbersome process and requires high accuracy. Chip technology helps perform precise CTC isolation but also helps overcome the challenges associated with isolation devices developed by key companies. The challenges include lower sensitivity, the inability to capture CTCs of all sizes & types, high manufacturing costs, and difficulty retrieving captured CTCs from the devices for further laboratory analysis. Moreover, the white blood cells that contaminate trapped CTCs, which are similar in size, can be mistakenly regarded as CTCs, a limitation associated with these devices.

These challenges can be overcome by developing a chip composed of carbon nanotubes. Researchers from the Worcester Polytechnic Institute, Massachusetts, developed a chip made of carbon nanotubes, which overcomes these challenges and boosts the capturing of CTCs, as reported in a research study published in April 2019. White blood cells do not adhere to the nanotubes, leaving only CTCs for enumeration. Another advantage of this chip is that it captures individual CTCs exhibiting multiple phenotypes from early- and late-stage cancer patients. Moreover, the CTCs captured by nanotubes remain viable and can even be cultured. As these chips are transparent, it makes it easier for researchers to stain and study captured CTCs without removing them.

Market Concentration & Characteristics

The market for CTCs has seen significant innovation in recent years. Some of the recent innovations include the development of microfluidic chips for CTC capture, the use of imaging techniques for circulating tumor cell detection, and the implementation of machine learning algorithms for CTC analysis. These advances can revolutionize cancer care by providing more accurate and reliable information about a patient's disease status.

The circulating tumor cells industry is also characterized by the leading players' high level of merger and acquisition (M&A) activity. M&A drives companies to focus on specific applications of CTC technology, such as early cancer detection, treatment monitoring, or personalized medicine. This could lead to more targeted and effective circulating tumor cell tests and therapies. For instance, in May 2023, Menarini Silicon Biosystems partnered with Alivio Health to provide access to its CELLSEARCH liquid biopsy tests for Alivio Health's clients and members. CELLSEARCH tests provide noninvasive analysis of CTCs to help in clinical decision-making, potentially leading to earlier diagnosis and more effective treatment strategies.

Regulations can have a significant impact on the CTC market. Regulatory bodies such as the FDA play a crucial role in determining the safety and efficacy of CTC products. Stringent regulations can lead to delays in approving new CTC products, which can slow innovation and limit the options available to patients and healthcare providers.

As the circulating tumor cells industry evolves, companies are expanding their product offerings through new technologies, strategic collaborations, and integration with multi-omics approaches. For instance, in December 2021, Epic Sciences launched DefineMBC, a blood-based test designed to improve care for patients with metastatic breast cancer.

As the CTC market grows, regional expansion plays a crucial role in increasing market penetration, regulatory approvals, and adoption rates. Increasing adoption in developing countries due to rising cancer cases & government initiatives is a major driver for regional expansion. For instance, China: CFDA (NMPA) has approved CellSearch for CTC detection, boosting hospital adoption.

Technology Insights

The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024. The availability of different methods to enrich circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period. Moreover, positive or negative enrichment of CTCs based on biological properties is expected to hold significant potential for market growth. An effective enrichment process helps enhance sensitivity, selectivity, and yield, thereby ensuring successful clinical translation of this field. Different techniques for CTC detection include magnetic beads-based centrifugal force, enrichment, filtration, and other physical properties such as density, deformity, size, & electric charges.

CTC analysis is expected to register the fastest CAGR during the forecast period. Understanding subclonal intratumor heterogeneity using CTC detection can help clinicians determine the underlying reasons for unresponsive patients subjected to targeted therapy, eventually leading to enhanced cancer therapies. Hence, CTC analysis is a minimally invasive method in repetitive analysis and validated technology for tumor study & clinical decision-making.

Moreover, technological advancements such as immunofluorescence, Next-Generation Sequencing (NGS), fluorescence in situ hybridization (FISH), and quantitative PCR (qPCR) are anticipated to improve CTC analyses. Hence, due to the fundamental principle of amplification in qPCR, the detection of CTCs in a large blood sample becomes efficient and accurate.

Application Insights

Clinical applications dominated the market and captured the largest revenue share in 2024. In a liquid biopsy, the analysis of CTCs in a cancer patient’s bloodstream has received significant attention for their potential clinical utility. The number of CTCs in a patient’s blood can differ based on cancer type, stage, and treatment. The number of CTCs found in the patient’s bloodstream indicates the state of the disease. Patients in the later stages of cancer show a higher number of CTCs than patients in the early stages of cancer.

The research segment is expected to register a significant CAGR during the forecast period. CTCs are regarded as a substrate of cancer metastasis. Currently, the enumeration of CTCs represents an effective predictive and prognostic biomarker capable of monitoring the efficacy of adjuvant therapies, identifying early development of metastases, and evaluating therapeutic responses better than conventional imaging methods. In addition, CTC enumeration remains largely a research tool.

Recently, the focus has shifted toward CTC characterization and isolation, which can provide significant opportunities in predictive testing research. For instance, in April 2021, Bio-Techne Corporation acquired Asuragen, Inc. for USD 215 million. Asuragen’s expertise in productizing lab-developed tests and commercializing innovative molecular products allowed Bio-Techne to offer advanced solutions to researchers and clinicians.

Product Insights

The kits & reagents segment dominated the market and accounted for the largest revenue share of 45.34% in 2024. This can be attributed to frequent purchases and high usage rates. For instance, CellSearch Circulating Tumour Cell Kit, authorized by the U.S. FDA, is one the most popular products produced in the U.S. In addition, the availability of a robust product portfolio coupled with advancements in microfluidics technology is expected to propel the market growth.

The devices or systems segment is expected to grow at the fastest CAGR during the forecast period. The introduction of fabricated glass microchips to overcome the challenges and to increase technical completeness for mass production is expected to propel the segment growth. The development of automated instruments that eliminate the use of additional blood collection tubes reduces the cost of blood collection tubes.

The cost reduction is also observed as transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used. On the other hand, kits and reagents have also contributed significantly to the segment’s revenue.

Specimen Insights

The blood specimen segment dominated the market and accounted for the largest revenue share of 48.13% in 2024. A large concentration of these cells in blood samples compared with other biospecimens is responsible for the largest penetration of this specimen type. Approaches for tumor cell identification in blood samples are considered important in current cancer research, as they aid in predicting prognosis and determining the response to systemic chemotherapy. However, using whole blood as a specimen poses a challenge when combined with microfluidic technology.

The bone marrow segment is expected to register a significant CAGR during the forecast period. Bone marrow samples, when analyzed for CTCs, play a vital role in cancer research and clinical trials. Researchers use these samples to study the biology of circulating tumor cells, understand the mechanisms of metastasis, and develop novel therapeutic approaches. These factors are expected to support segment growth in the forecast years.

End Use Insights

Hospital and clinics dominated the market and accounted for the largest revenue share of 37.64% in 2024. This is due to their advanced technology and expertise in detecting and analyzing CTCs. They have access to advanced equipment and trained professionals who can perform accurate and reliable tests. The large share of the segment is due to direct patient care, treatment planning, and integration with oncology departments. Moreover, the increasing adoption of liquid biopsy for cancer monitoring is also attributed to segment growth.

Research and academic institutes.is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing focus on research and development activities for cancer diagnosis and treatment. These institutes invest heavily in advanced technologies and equipment to enhance CTC detection and analysis accuracy and efficiency.

Competitive Analysis

The table evaluates key circulating tumor cell market players based on parameters such as product portfolio, strategic initiatives, and geographic presence. QIAGEN, Bio-Rad Laboratories, and Miltenyi Biotec exhibit high scores across all parameters, indicating a strong product portfolio, strategic initiatives, and global presence. These companies are well-positioned in the market due to their broad offerings and international reach. Ikonisys Inc. and Creative Biolarray show medium rankings in strategic initiatives while maintaining high scores in other areas. This suggests that while they have strong market penetration, they may need to enhance their strategic initiatives to remain competitive. Bio-Techne Corporation and Epic Sciences have room for growth in expanding collaborations, partnerships, and innovation strategies.

Regional Insights

North America captured the largest market share of 40.91% in 2024. The key players operating in the region are undertaking various strategies to enhance their market hold, a key factor responsible for the high share of the U.S. The U.S. is anticipated to significantly contribute to the regional market's growth due to factors including the rising incidence of cancer, product approvals, and increased R&D efforts. For instance, the American Cancer Society projects that there are approximately 127,070 lung cancer fatalities nationwide and about 238,340 new instances of lung cancer diagnosis in 2023. Furthermore, a population with high cancer susceptibility, increased market penetration rates, and technologically advanced cancer care infrastructure support the region’s growth.

U.S. Circulating Tumor Cells Market Trends

The circulating tumor cells industry in the U.S. benefits from extensive clinical research activities and the strong presence of biotechnology firms developing innovative CTC isolation technologies. The country's favorable regulatory environment for liquid biopsy products and growing investment in precision oncology are accelerating the adoption of CTC-based tests for monitoring treatment response and detecting minimal residual disease.

Europe Circulating Tumor Cells Market Trends

The CTC market in Europe is expanding due to the increasing adoption of liquid biopsy solutions for cancer management. Research institutions and healthcare providers across the region are actively exploring CTC technologies for early detection, prognosis, and therapy monitoring. Strong regulatory support and funding for oncology research are further accelerating market growth.

The UK circulating tumor market is experiencing significant growth due to growing investments in precision medicine initiatives. Collaborative research projects drive the development of CTC-based diagnostic tools. The National Health Service (NHS) is progressively adopting liquid biopsy methods, supporting the demand for CTC technologies in clinical practice.

The circulating tumor market in Germany is growing due to their well-established healthcare infrastructure, coupled with strong academic research in oncology, which is propelling the adoption of CTC analysis. The country's focus on developing advanced cancer diagnostic tools and increased funding for personalized medicine projects are major growth drivers.

Asia Pacific Circulating Tumor Cells Market Trends

The circulating tumor cells market in Asia Pacific is witnessing growing demand for CTC technologies due to an increasing cancer burden, rising healthcare expenditure, and expanding research initiatives. Countries like China and Japan invest heavily in developing liquid biopsy tools, boosting market growth. Government support for cancer diagnostics and growing awareness about non-invasive testing further propel adoption.

China circulating tumor cells industry growth is driven by increasing investments in biotechnology research and collaborations between domestic and international firms. The country's focus on precision medicine and rising cancer incidence have created significant demand for CTC-based diagnostic tools, particularly for lung and gastric cancers.

The circulating tumor cells market in Japan is growing due to advancements in molecular diagnostics and strong research capabilities. The country's emphasis on early cancer detection and personalized medicine has increased the integration of CTC analysis in clinical practice, particularly for breast and prostate cancer.

MEA Circulating Tumor Cells Market Trends

The circulating tumor cells (CTC) market in the Middle East & Africa is gaining momentum due to increasing investments in healthcare infrastructure and growing awareness of advanced cancer diagnostics. The region’s rising cancer burden and efforts to improve early detection and personalized medicine moderately drive demand for innovative technologies like CTC analysis. Partnerships between healthcare institutions and global biotech firms are further accelerating the adoption of liquid biopsy solutions.

Saudi Arabia CTC market is supported by the government's healthcare reforms under Vision 2030, which emphasize advanced diagnostic technologies and improved cancer care. Rising investments in precision medicine and initiatives to enhance oncology research capabilities are fostering demand for CTC-based testing for early detection and monitoring of metastatic cancers.

The circulating tumor cells market in Kuwait is growing significantly due to the growing prevalence of cancer and increasing investments in diagnostic innovations. The country's healthcare sector is expanding its focus on precision oncology, with medical institutions exploring noninvasive methods like CTC analysis to improve cancer diagnosis, prognosis assessment, and treatment monitoring.

Key Circulating Tumor Cells Company Insights

Key players mostly adopted partnerships, acquisitions, and expansion strategies. Companies such as Bio-Techne have acquired smaller companies with advanced technologies to expand their market reach globally.

Recent Developments

• In March 2024, Bio-Rad Laboratories, Inc. launched validated antibodies for rare cell and circulating tumor cell (CTC) enumeration, enhancing tools available for CTC research and diagnostics.

• In August 2023, Cell Microsystems acquired Fluxion Biosciences, Inc. This acquisition enabled precise measurement of electrical currents across cell membranes, providing insights into ion channel activity and cell signaling.

• In June 2023, Bio-Techne announced the acquisition of LunaPhore, a Swiss company developing advanced tissue imaging and analysis technologies. By integrating LunaPhore's expertise into its existing portfolio, Bio-Techne aimed to create a comprehensive, end-to-end workflow for researchers studying tissues. The acquisition is expected to close in the first quarter of 2024.

• In March 2023, Miltenyi Biotec acquired Lino Biotech AG. This acquisition of Lino Biotech's innovative biosensor technology was expected to help develop new & improved assays and quality control processes in the field.

Circulating Tumor Cells Market